Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

France’s Sanofi Pasteur Adopts “High State Of Readiness” To Produce Global Vaccine Defense Arsenal If H1N1 Evolves Into Pandemic: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

Immediately after the Director-General of the World Health Organization raised the pandemic alert level from phase 4 to phase 5, just one step below notification of a global health threat, an influenza expert at Sanofi Pasteur outlined the French-based vaccine maker's response: moving into a "high state of readiness" to help create a worldwide vaccine defense to the speedening spread of H1N1. Sanofi Pasteur is a global power in terms of vaccine production, turning out 1.6 billion vaccine doses in 2008, and specialist Albert Garcia at Pasteur's headquarters in Lyon, France provided an overview on how the outfit's operations in the Americas, Europe and Asia could be mobilized in a worldwide fight against H1N1.
Advertisement
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

SC071675

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel